5061972026-07-012026-09-305061972026-09-305061972026-03-315061972026-04-012026-09-305061972026-07-012026-09-30in-capmkt:OtherExpenses1Member5061972026-07-012026-09-30in-capmkt:OtherExpenses2Member5061972026-07-012026-09-30in-capmkt:OtherExpenses3Member5061972026-07-012026-09-30in-capmkt:OtherExpenses4Member5061972026-07-012026-09-30in-capmkt:OtherExpenses5Member5061972026-07-012026-09-30in-capmkt:OtherExpenses6Member5061972026-07-012026-09-30in-capmkt:OtherExpenses7Member5061972026-07-012026-09-30in-capmkt:OtherExpenses8Member5061972026-07-012026-09-30in-capmkt:OtherExpenses9Member5061972026-07-012026-09-30in-capmkt:OtherExpenses10Member5061972026-04-012026-09-30in-capmkt:OtherExpenses1Member5061972026-04-012026-09-30in-capmkt:OtherExpenses2Member5061972026-04-012026-09-30in-capmkt:OtherExpenses3Member5061972026-04-012026-09-30in-capmkt:OtherExpenses4Member5061972026-04-012026-09-30in-capmkt:OtherExpenses5Member5061972026-04-012026-09-30in-capmkt:OtherExpenses6Member5061972026-04-012026-09-30in-capmkt:OtherExpenses7Member5061972026-04-012026-09-30in-capmkt:OtherExpenses8Member5061972026-04-012026-09-30in-capmkt:OtherExpenses9Member5061972026-04-012026-09-30in-capmkt:OtherExpenses10Member5061972026-09-30OtherNoncurrentFinancialAssetsDomain15061972026-09-30OtherNoncurrentFinancialAssetsDomain25061972026-09-30OtherNoncurrentAssetsDomain15061972026-09-30OtherNoncurrentAssetsDomain25061972026-09-30OtherCurrentFinancialAssetsDomain15061972026-09-30OtherCurrentAssetsDomain15061972026-09-30OtherNoncurrentFinancialLiabilitiesDomain15061972026-09-30OtherNoncurrentFinancialLiabilitiesDomain25061972026-09-30OtherNoncurrentLiabilitiesDomain15061972026-09-30OtherCurrentFinancialLiabilitiesDomain15061972026-09-30OtherCurrentFinancialLiabilitiesDomain25061972026-09-30OtherCurrentLiabilitiesDomain15061972026-07-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15061972026-04-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15061972026-07-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15061972026-04-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares506197BLISSGVSNOTLISTEDINE416D01022BLISS GVS PHARMA LIMITEDMain BoardEquity2026-04-012027-03-312026-10-292026-10-22INRLakhsQuarterlySecond quarterSingle segmentPharmaceutical and Healthcare2026-10-2914:30:002026-10-2916:00:00trueCash Flow IndirectNot applicable2026-07-012026-09-30UnauditedConsolidated31336700008304900032167190001358238000117157000-2808200004499200003296000010495700068332900024657410007509780000750978000210059000749900021755800005334200000000533420000-16625000516795000522522000108980005058970001089800010633000014.924.81004.924.81Notes: <br /> <br /> 1. The above unaudited standalone and consolidated financial results, which are published in accordance with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on October 29, 2026. These unaudited standalone and consolidated financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards (“Ind AS”) as prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. <br /> <br /> 2. The above unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, have been prepared in compliance with Ind AS and have been subjected to a limited review by the statutory auditors of the Company. The statutory auditors have issued limited review reports with unmodified conclusions on the unaudited standalone and consolidated financial results. <br /> <br /> 3. As the Group’s business activity falls within a single operating segment, viz. “Pharmaceutical and Healthcare”, no segment information is disclosed. <br /> <br /> 4. Employee benefit expenses include share-based payment expense on account of the ESOP Scheme, 2019, of Rs.698.82 lakh (half year ended September 30, 2025: Rs.314.04 lakh), as per Ind AS 102, “Share-based Payment”, for the half year ended September 30, 2026. <br /> <br /> 5. During the half year ended September 30, 2026, the Company allotted 5,41,500 equity shares of Rs.1 each, fully paid-up, on exercise of stock options by employees in accordance with the Company’s ESOP Scheme, 2019. The outstanding number of options as at September 30, 2026, is 23,81,000. Further, subsequent to the period end, the Company allotted 53,500 equity shares of Rs.1 each, fully paid-up, on exercise of stock options by employees in accordance with the Company’s ESOP Scheme, 2019. <br /> <br /> 6(a). In the standalone financial results, exceptional items for the quarter and half year ended September 30, 2026, represent a reversal of the impairment provision of Rs.4,108.61 lakh. The provision had been recognised during the quarter and year ended March 31, 2024, on the Company’s investments in its wholly owned subsidiary, Bliss GVS International Pte. Ltd. (Singapore), which then had a negative consolidated net worth. The financial performance of the said subsidiary has improved through its step-down subsidiaries, and its net worth has turned positive as at the balance sheet date, with no immediate risk to its going concern. Based on its reassessment, Management has reversed the impairment provision. <br /> <br /> 6(b). Pursuant to the implementation of the New Labour Codes with effect from November 21, 2025, the Company and the Group reassessed their employee benefit obligations and recognised an incremental expense of Rs.215.55 lakh and Rs.248.71 lakh in the standalone and consolidated financial statements, respectively, for the year ended March 31, 2026, under exceptional items as past service cost. <br /> <br /> 7. Pursuant to the Share Purchase Agreement dated May 23, 2026, and the open offer under the SEBI (SAST) Regulations, 2011, Anupam Rasayan India Limited, together with Mates Visa Consultancy Private Limited (person acting in concert), acquired 5,32,36,264 equity shares, representing 50.07% of the paid-up equity share capital of the Company. Accordingly, with effect from September 28, 2026, Anupam Rasayan India Limited became the holding company and promoter of the Company. The Board of Directors was reconstituted on the same date. The change in control has no impact on the financial results of the Company for the quarter and half year ended September 30, 2026.2026-04-012026-09-30UnauditedConsolidated598942600017904600061684720002304603000268138000-2337210008803920003875400020433200012001650004662663000150580900001505809000376388000822810004586690000104714000000001047140000-3841900010087210001023496000236440009850770002364400010633000019.659.46009.659.46Freight outward147376000ECL expenses90649000Travelling and Conveyance expenses32123000Repairs and Maintenance47833000Power and Fuel52058000Business Development expenses148864000Corporate Social Responsibility expenses28240000Sales Promotion expenses11824000Legal and Professional Charges52780000Others71582000Freight outward248490000ECL expenses150299000Travelling and Conveyance expenses58676000Repairs and Maintenance83980000Power and Fuel115164000Business Development expenses262267000Corporate Social Responsibility expenses28385000Sales Promotion expenses18839000Legal and Professional Charges103900000Others130165000461481900080353000680500077111000681600038623000007772590008158820008050300015127500058335640001883020000056693470003681380001142323000107000416324000759623900005103060009989565000001582312900010633000012797117000129034470004104400001331388700000001804320001804320003033100000135000210898000031243300091018700012226200006012700001823890000103456000416200003293780000229834400000250924200015823129000Investments0Other Financial Assets777259000Income Tax Asset (Net)31277000Other Non-Current Assets119998000Other Financial Assets416324000Other Current Assets510306000Lease Liabilities168324000Other Financial Liabilities12108000Other Non-Current Liabilities135000Other Financial Liabilities544024000Lease Liabilities57246000Other Current Liabilities10345600038754000-404974000-813204000044990001901000-7958000632500001880150000-6651000-670002043320000-29482000-3759000-1273560000157453000100007571900069882000-1632550000-74910002440001951610000-773360000732449000000347907000-2760400035693800000337444000317601000000039900031702700000000000000073376000000010000712850000148774000-150092000002328500000000029262000411600001071870003780400004109000-18801900018827000-210500016722000351416000368138000Remeasurement of the defined benefit liabilities/ (asset)29960002996000Remeasurement of the defined benefit liabilities/ (asset)-5638000-5638000754000-1419000Exchange differences in translating the Financial Statements of Foreign Operations-18867000-18867000Exchange differences in translating the Financial Statements of Foreign Operations-34200000-3420000000-16625000-38419000